Regeneron’s fast-acting IgG promises alternative to frequent allergy shots

The week brought only one big stock move on a clinical catalyst, with Rapport Therapeutics Inc. doubling in value on proof of concept in epilepsy. More quietly, Regeneron reported data from a new approach to allergy treatment that flew under investors’ radar, despite promising to reshape a field with little innovation.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced readouts from two Phase III trials testing different pairs of allergen-blocking mAbs in patients with moderate-to-severe cat or birch allergies, despite receiving standard-of-care histamine blockers or steroids. One trial evaluated REGN1908 and REGN1909, which target FelD1, the most dominant cat allergen. The other tested REGN5713 and REGN5715, which target BetV1, the dominant allergenic protein in birch pollen...